Human TRAIL R3/TNFRSF10C Antibody Summary
Ala26-Ala221
Accession # O14798
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of Human TRAIL R3/TNFRSF10C by Western Blot. Western blot shows lysates of L-929 mouse fibroblast cell line, THP-1 human acute monocytic leukemia cell line, and WS-1 human fetal skin fibroblast cell line. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human TRAIL R3/TNFRSF10C Antigen Affinity-purified Polyclonal Antibody (Catalog # AF630) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for TRAIL R3/TNFRSF10C at approximately 27 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
View Larger
TRAIL R3/TNFRSF10C Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R3/TNFRSF10C Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (5 µg/mL, Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (Catalog # 630-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/ TNFSF10 (12 ng/mL) activity elicited by Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TRAIL R3/ TNFRSF10C Antigen Affinity-purified Polyclonal Antibody (Catalog # AF630). The ND50 is typically 0.015-0.045 µg/mL.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TRAIL R3/TNFRSF10C
Human TRAIL R3, also called DcR1 (decoy receptor 1), LIT, and TRID, is a glycosyl-phosphatidylinositol-linked membrane protein which binds TRAIL (Apo2 Ligand) with high affinity. In the new TNF superfamily nomenclature, TRAIL R3 is referred to as TNFRSF10C. TRAIL R3 has the TRAIL-binding extracellular cysteine-rich domains but lacks the intracellular signalling domain. As a result, binding of TRAIL to TRAIL R3 does not transduce an apoptosis signal. Expression of TRAIL R3 has been shown to protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-induced apoptosis. A second TRAIL decoy receptor, which binds TRAIL with high-affinity but antagonizes TRAIL-induced apoptosis, named TRAIL R4, DcR2 or TRUNDD, has also been reported. The human soluble TRAIL R3/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.
Product Datasheets
Citations for Human TRAIL R3/TNFRSF10C Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
10
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models
Authors: M Kopczynski, M Statkiewic, M Cybulska, U Kuklinska, K Unrug-Biel, Z Sandowska-, A Grochowska, M Gajewska, M Kulecka, J Ostrowski, M Mikula
International Journal of Molecular Sciences, 2021-03-19;22(6):.
Species: Human
Sample Types: Whole Cells
Applications: ICC -
Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B more Efficiently than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors
Authors: ?? ?rtykov, DA Belov, VO Shipunova, DB Trushina, SM Deyev, DA Dolgikh, MP Kirpichnik, ME Gasparian
Cancers (Basel), 2020-04-30;12(5):.
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture -
TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.
Authors: Wu CH, Kao CH, Safa AR
Hum. Gene Ther., 2008-07-01;19(7):731-43.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Authors: Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M
Int. J. Oncol., 2007-12-01;31(6):1391-402.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Authors: Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR
Biochem. Pharmacol., 2006-05-04;72(3):293-307.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
Authors: Lane D, Cote M, Grondin R, Couture MC, Piche A
Mol. Cancer Ther., 2006-03-01;5(3):509-21.
Species: Human
Sample Types: Whole Cells
Applications: Western Blot -
Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
Authors: Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL
Biochem. Biophys. Res. Commun., 2005-07-22;333(1):42-50.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
Authors: Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P
Circ. Res., 2003-03-20;92(7):732-40.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Authors: Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC
Oncogene, 2002-08-22;21(37):5673-83.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
Authors: Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR
Cell Death Differ., 2002-03-01;9(3):274-86.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human TRAIL R3/TNFRSF10C Antibody
There are currently no reviews for this product. Be the first to review Human TRAIL R3/TNFRSF10C Antibody and earn rewards!
Have you used Human TRAIL R3/TNFRSF10C Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
